Naz Rahman
Stock Analyst at Maxim Group
(0.30)
# 4,218
Out of 4,955 analysts
36
Total ratings
19.35%
Success rate
-41.51%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.47 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $6.36 | +167.30% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $6.80 | +1,002.94% | 2 | Mar 20, 2025 | |
| SCPH scPharmaceuticals | Maintains: Buy | $20 → $12 | $4.56 | +163.16% | 3 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $25.66 | +172.80% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.14 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $3.99 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $0.73 | +1,001.93% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $1.63 | - | 2 | Oct 24, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $3 | $0.77 | +289.61% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $7.28 | +1,822.81% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $397.46 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.21 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $2.18 | +129.36% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.25 | +166.67% | 1 | Feb 25, 2022 |
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.47
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $6.36
Upside: +167.30%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $6.80
Upside: +1,002.94%
scPharmaceuticals
Mar 20, 2025
Maintains: Buy
Price Target: $20 → $12
Current: $4.56
Upside: +163.16%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $25.66
Upside: +172.80%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.14
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $3.99
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $0.73
Upside: +1,001.93%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.63
Upside: -
Assertio Holdings
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.77
Upside: +289.61%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $7.28
Upside: +1,822.81%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $397.46
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.21
Upside: -
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $2.18
Upside: +129.36%
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.25
Upside: +166.67%